vimarsana.com

Page 269 - Software Developers News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Secarna Pharmaceuticals publishes new preclinical data in The Journal of Immunology demonstrating potent therapeutic activity of LNAplus™ ASO targeting NLRP3 in highly debilitating autoinflammatory diseases

<ul> <li> Secarna s LNAplus™ ASOs suppress expression of NLRP3, a central component of the inflammasome pathway, which is overactive in many inflammatory diseases </li> <li> Cryopyrin-associated periodic syndrome (CAPS) is a group of rare inherited autoinflammatory diseases driven by overactive NLRP3, resulting in systemic inflammation </li> <li> With NLRP3-specific ASOs, inflammatory downstream effects were interrupted in immune cells and strong symptom relief and significant prolongation of survival was achieved in a CAPS disease model.</li></ul>

Global V2X Market for Vehicle to Everything to 2028: by Connection Type, Communications Type, Vehicle Autonomy Level, Safety and Commercial Applications - ResearchAndMarkets com

Global V2X Market to 2028: Combined 5G and Mobile Edge Computing Solutions to Accelerate Growth

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.